

September 8, 2021  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**SymBio announces initiation of non-clinical study of brincidofovir IV  
at the Brain Tumor Center, Department of Neurological Surgery  
University of California, San Francisco**

TOKYO, Japan, September 8, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that a non-clinical study to investigate the anti-tumor efficacy of brincidofovir IV (BCV) against brain tumors was initiated at the Brain Tumor Center, Department of Neurological Surgery, University of California, San Francisco (UCSF).

The principal investigator of this study, Tomoko Ozawa, M.D., Ph.D. (Co-Director, UCSF Brain Tumor Center Preclinical Therapeutic Testing Core) commented that she is hopeful that the findings from the study will lead to new treatments for refractory brain tumors.

Statement from Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio: "BCV has a wide range of antiviral effects against dsDNA viruses and is expected to have antitumor effect. This study will help to elucidate the effects of BCV on refractory brain tumors and its mechanism of action, and is aimed toward the development of new therapies."

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2021.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

### **About Anti-viral Drug Brincidofovir**

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox).

### **About UCSF Brain Tumor Center**

It is one of the leading medical institutions in the United States that provides state-of-the-art molecular tumor profiling, targeted drug treatment, non-drug treatment, and radiotherapy for brain tumors. It has over 25 state-of-the-art research and the largest clinical trial program in the country to develop new therapies for refractory tumors.

<https://braintumorcenter.ucsf.edu/why-choose-ucsf-brain-tumor-care>

### **About Chimerix**

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U. S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. Chimerix has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M- mutant glioma and blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia. For further information, please visit the Chimerix website, [www.chimerix.com](http://www.chimerix.com).

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.